Metabolic homeostasis in mammals is tightly regulated by the complementary actions of
insulin and glucagon. The secretion of these hormones from pancreatic β-cells and α-cells …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Nutrient-deprived conditions in the tumor microenvironment (TME) restrain cancer cell
viability due to increased free radicals and reduced energy production. In pancreatic cancer …

Metabolic fuels regulate insulin secretion by generating second messengers that drive
insulin granule exocytosis, but the biochemical pathways involved are incompletely …

Chondrosarcomas constitute a heterogeneous group of primary bone cancers characterized
by hyaline cartilaginous neoplastic tissue. They are the second most common primary bone …

Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1) R132C and R132H variants, is
approved for the treatment of acute myeloid leukaemia (AML). Resistance to ivosidenib due …

Mutant isocitrate dehydrogenase 1 (IDH1-R132H; mIDH1) is a hallmark of adult gliomas.
Lower grade mIDH1 gliomas are classified into 2 molecular subgroups: 1p/19q …

Abstract Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated
metabolic genes across human cancers. These hotspot gain‐of‐function mutations cause …

Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human
glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 …